(Q34659375)

3 August 2017

1 reference

title

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis (English)

1 reference

3 August 2017

1 reference

Gharib MI

1

1 reference

3 August 2017

Burnett AK

series ordinal

2

1 reference

3 August 2017

publication date

1 June 2002

1 reference

European Journal of Heart Failure

3 August 2017

published in

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

235-242

1 reference

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardiovascular toxicity with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac Catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Early anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Outcome of clinical congestive heart failure induced by anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Dose-effect and structure-function relationships in doxorubicin cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Alterations in left ventricular diastolic function with doxorubicin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardiac diastolic function in pediatric patients receiving doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Impairment of diastolic function during short-term anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Elevated B-type natriuretic peptide levels after anthracycline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Plasma endothelin-1 and doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Increased risk of cardiac dysfunction after anthracyclines in girls

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Persistent Effects of Doxorubicin on Cardiac Gene Expression

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Endomyocardial biopsy to monitor anthracycline therapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Mitoxantrone: an overview of safety and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Cardiac changes with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2801%2900201-X

7 January 2021

10.1016/S1388-9842(01)00201-X

Identifiers

DOI

1 reference

release_d3jpes2zwfdkfcuizqoznd7buu

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d3jpes2zwfdkfcuizqoznd7buu

24 November 2022

mapped directly with Wikidata item

1 reference